U.S. markets open in 1 hour 3 minutes

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1152-0.0088 (-7.10%)
At close: 3:55PM EDT
Sign in to post a message.
  • G
    Gee
    Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19

    10/22/2020

    Tetra, Targeted Pharmaceutical and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration

    ARDS-003 to be evaluated in Sars-CoV-2 infected animals at the Biocontainment Laboratory-George Mason University NCBID
  • L
    Lloyd
    So management holds a town hall yesterday and Guy states the share price is low due to manipulation.

    Today they finalize the divestment of Lumiera to Mondias where there is literally no benefit to Tetra.

    But it’s the manipulation guys. Dark pools this, 007 that.
  • L
    Long-John
    It’s been a long wait and an even deeper drop, but it does seem that the company is connecting the dots and setting a clear direction. I’m cautiously optimistic.
  • R
    Rocnon
    someone is working hard to keep the price down. over the last week I have bought several 10k blocks all under my bid price. they want you to sell out now. I will continue to purchase at these levels for as long as it takes. could last for a while so run away if you don't have the stomach for extreme risk. I believe we are within nine months of a real multi front break through. I can wait, can you?
    Bullish
  • C
    ChanChan
    Woohoo! 0.18!
  • e
    efriam
    I believe Tetra is finally turning things around
    Bullish
  • D
    D
    Anyone else experiencing difficulties posting on this message bd?
    Bullish
  • C
    Chris
    Great news
    Should rocket on this news back to 50 cents we go
  • d
    dennis
    Lloyd there is only one way in which sp can be manipulated, and that is if there is low volume. Volume is low because there is no confidence in management.
  • N
    Nedster
    Tetra Bio-Pharma (TBP) Acquires Dronabinol Soft Gel Capsules Exclusive Canadian Distribution Rights to Establish a Strong Commercial Presence in Canada and Accelerate its Profitability
    Tetra is ready to submit its first New Drug Submission application to commercialize a THC-based prescription drug in Canada.

    Will facilitate the introduction of CAUMZTM
    Significantly reinforce our core business
    Allows Tetra to establish a revenue stream
    OTTAWA, ON / ACCESSWIRE / September 30, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP.TO)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, announced today that it has entered into a definitive agreement with a USA strategic partner to acquire the Canadian exclusive rights for Dronabinol Soft Gel capsules. Tetra will be submitting a New Drug Submission application in fiscal Q4 2020 to obtain its first DIN (Drug Identification Number) for a THC-based prescription drug.

    The acquisition will allow Tetra to establish an immediate and direct commercial presence in Canada by promoting an existing cannabinoid derived prescription drug. This will allow Tetra to establish a revenue stream based on a synthetic cannabinoid drug for major markets in Chemotherapy Induced Nausea and Vomiting (CINV). The experience gained with Dronabinol will help to pave the way for the introduction of CAUMZTM to the marketplace. The addressable market is estimated to be $80M CDN by 2022(1). Tetra's intention is to gain experience with a cannabinoid derived medicine in the Canadian market in order to acquire strategic insight so that this will strengthen our discussion at the Global level with our partners.

    Under the terms of the agreement, TBP has agreed to acquire Dronabinol Soft Gel capsules commercial rights for two undisclosed milestones, 50% at the approval of the transaction and the other 50% once the DIN is granted by Health Canada.

    Dronabinol Soft Gel capsules are indicated in AIDS-related anorexia associated with weight loss and severe nausea and vomiting associated with cancer chemotherapy. Dronabinol DIN launch is expected in the first-half of 2021.

    Dr. Guy Chamberland, CEO and CRO of Tetra commented: "This transaction is a key milestone for Tetra, as this will allow us to generate revenues. On the regulatory front, securing the Dronabinol data pack will allow TBP to move quickly to filing its New Drug Submission application, and expedite several of our future investigational new drug submissions including but not limited to PPP-002."

    "The acquisition of Dronabinol soft gel capsules enables Tetra to accelerate its goal towards profitability and meet its strategic goal to become a key player in cannabinoid derived medicines globally. It is a major step in the transformation of the Company, allowing us to establish a direct commercial presence in Canada, so that when we introduce CAUMZTM we will be able to anticipate success stories and barriers. In the current context of cannabis legalization and significant shortages of nabilone, a drug used for chemotherapy-induced nausea and vomiting, our goal is to relaunch a high value therapeutic option with robust data. My goal has always been to address patients, healthcare professionals and shareholders expectations", said Steeve Néron, Chief Commercial Officer.

    1Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron) - Global Opportunities and Forecast 2014-2022 Allied Market Research (assuming 3% market share in Canada)

    About Tetra Bio-Pharma

    Tetra Bio-Pharma (TSX:TBP.TO)(OTCQB:TBPMF), is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a FDA and a Health Canada approved clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.

    For more information visit: www.tetrabiopharma.com
  • L
    Leafs 79
    Building the foundation brick by brick
  • L
    Long-John
    What will ARDS-003 be used for? General anti-inflammatory purposes? Cytokines storm has been proven not to be a condition of covid, as I’m sure you all know.
  • C
    ChanChan
    “Tetra Bio-Pharma Announces Positive Results in Animal Studies for Treatment of Hyperinflammatory Lung Injury” GREAT NEWS!
    CA$0.18 here we come!
  • a
    anthony
    TBP could cure cancer and we would still go down
  • K
    Kevin
    0 volume today???? What’s the deal????
  • C
    ChanChan
    Almost no volume today???? What’s the deal???? Aren’t buyers thankful for this Chamberland gem?????
  • Y
    Yagu S
    This is massive. Revenue coming. Also setting the stage for CAUMZ entry into the cancer pain market
  • L
    Long-John
    I’m not really sure that I understand this move to buy Dronabinol and the implications. Anyone care to explain?